688506 百利天恒
已收盘 12-31 15:00:00
资讯
新帖
简况
百利天恒:拟1亿元~2亿元回购股份 回购价格不超过546元/股
每日经济新闻 · 12-30 18:50
百利天恒:拟1亿元~2亿元回购股份 回购价格不超过546元/股
百利天恒拟发行不超过100亿元债务融资工具
美股速递 · 12-28
百利天恒拟发行不超过100亿元债务融资工具
百利天恒最新公告:拟申请注册发行不超过100亿元债务融资工具
证券之星 · 12-28
百利天恒最新公告:拟申请注册发行不超过100亿元债务融资工具
每周股票复盘:百利天恒(688506)控股股东限售股将解禁并承诺不减持
证券之星 · 12-28
每周股票复盘:百利天恒(688506)控股股东限售股将解禁并承诺不减持
百利天恒(688506)披露首次公开发行部分限售股上市流通暨控股股东、实际控制人自愿承诺不减持的公告,12月25日股价下跌3.22%
证券之星 · 12-25
百利天恒(688506)披露首次公开发行部分限售股上市流通暨控股股东、实际控制人自愿承诺不减持的公告,12月25日股价下跌3.22%
百利天恒宣布2.981亿股限售股即将解禁,1月6日起上市流通
美股速递 · 12-25
百利天恒宣布2.981亿股限售股即将解禁,1月6日起上市流通
12月18日百利天恒现292.42万元大宗交易
证券之星 · 12-18
12月18日百利天恒现292.42万元大宗交易
四川新首富豪赌创新药:叫停港股IPO,百利天恒的“输血”与“造血”困局
华夏时报 · 12-10
四川新首富豪赌创新药:叫停港股IPO,百利天恒的“输血”与“造血”困局
百利天恒收到里程碑付款;迈威生物披露阻塞性肺病新药临床进展|医药早参
每日经济新闻 · 12-01
百利天恒收到里程碑付款;迈威生物披露阻塞性肺病新药临床进展|医药早参
四川百利天恒表示仍有资格获得高达2.5亿美元的短期付款,以及在达到特定研发、监管、商业里程碑后获得高达71亿美元的额外付款
美股速递 · 11-30
四川百利天恒表示仍有资格获得高达2.5亿美元的短期付款,以及在达到特定研发、监管、商业里程碑后获得高达71亿美元的额外付款
百利天恒宣布其子公司近期已从施贵宝获得2.5亿美元里程碑付款,涉及Iza-Bren全球战略协议
美股速递 · 11-30
百利天恒宣布其子公司近期已从施贵宝获得2.5亿美元里程碑付款,涉及Iza-Bren全球战略协议
百利天恒(688506.SH)子公司收到与百时美施贵宝就iza-bren项目里程碑付款2.5亿美元
智通财经 · 11-30
百利天恒(688506.SH)子公司收到与百时美施贵宝就iza-bren项目里程碑付款2.5亿美元
百利天恒(688506)披露召开2025年第三季度业绩说明会公告,11月27日股价下跌0.85%
证券之星 · 11-27
百利天恒(688506)披露召开2025年第三季度业绩说明会公告,11月27日股价下跌0.85%
百利天恒:截至2025年9月30日,股东户数为5979户
证券日报 · 11-25
百利天恒:截至2025年9月30日,股东户数为5979户
四川百利天恒与中国银行四川省分行签署不少于80亿元的信贷协议
美股速递 · 11-19
四川百利天恒与中国银行四川省分行签署不少于80亿元的信贷协议
百利天恒(688506.SH):iza-bren用于复发性或转移性食管鳞癌的III期临床试验的期中分析达到主要终点
智通财经 · 11-18
百利天恒(688506.SH):iza-bren用于复发性或转移性食管鳞癌的III期临床试验的期中分析达到主要终点
每周股票复盘:百利天恒(688506)H股上市延迟
证券之星 · 11-16
每周股票复盘:百利天恒(688506)H股上市延迟
百利天恒IPO延迟!“A+H”还要等多久?
投资时报 · 11-14
百利天恒IPO延迟!“A+H”还要等多久?
688506,港股IPO延迟!
中国基金报 · 11-13
688506,港股IPO延迟!
百利天恒(688506)披露关于发行H股并上市的进展公告,11月12日股价上涨2.49%
证券之星 · 11-12
百利天恒(688506)披露关于发行H股并上市的进展公告,11月12日股价上涨2.49%
加载更多
公司概况
公司名称:
四川百利天恒药业股份有限公司
所属行业:
医药制造业
上市日期:
2023-01-06
主营业务:
四川百利天恒药业股份有限公司的主营业务是创新生物药业务板块和化药制剂、中成药制剂业务板块。公司的主要产品是丙泊酚乳状注射液、丙泊酚中/长链脂肪乳注射液、吸入用七氟烷、结构脂肪乳注射液、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。
发行价格:
24.70
{"stockData":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恒","latestPrice":323.1,"timestamp":1767164400000,"preClose":322.66,"halted":0,"volume":680714,"delay":0,"changeRate":0.0014,"floatShares":103000000,"shares":413000000,"eps":-2.0646,"marketStatus":"已收盘","change":0.44,"latestTime":"12-31 15:00:00","open":325.98,"high":326.17,"low":320.99,"amount":220000000,"amplitude":0.0161,"askPrice":323.23,"askSize":0,"bidPrice":323.1,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-2.0646,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767576600000},"marketStatusCode":5,"adr":0,"adjPreClose":322.66,"symbolType":"stock_kcb","openAndCloseTimeList":[[1767144600000,1767151800000],[1767157200000,1767164400000]],"highLimit":354.93,"lowLimit":290.39,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":412873817,"isCdr":false,"pbRate":18.6,"roa":"--","roe":"--","epsLYR":9.25,"committee":-0.183673,"marketValue":133400000000,"turnoverRate":0.0066,"status":0,"afterMarket":{"amount":0,"volume":0,"close":323.1,"buyVolume":0,"sellVolume":0,"time":1767166437558,"indexStatus":"已收盘 12-31 15:30:00","preClose":322.66},"hkstockBrief":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"百利天恒","latestPrice":0,"timestamp":1767153600000,"preClose":0,"halted":7,"volume":0,"delay":0,"premium":"-100.00"},"floatMarketCap":33244000000},"requestUrl":"/m/hq/s/688506","defaultTab":"news","newsList":[{"id":"2595799938","title":"百利天恒:拟1亿元~2亿元回购股份 回购价格不超过546元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2595799938","media":"每日经济新闻","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595799938?lang=zh_cn&edition=full","pubTime":"2025-12-30 18:50","pubTimestamp":1767091842,"startTime":"0","endTime":"0","summary":"每经AI快讯,12月30日,百利天恒(688506.SH)公告称,公司拟以集中竞价交易方式回购公司股份,回购金额不低于1亿元且不超过2亿元,回购价格不超过546元/股。回购的股份将在未来适宜时机全部用于实施员工持股计划或股权激励。若公司未能在股份回购实施结果暨股份变动公告日后3年内使用完毕已回购股份,尚未使用的已回购股份将予以注销。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512303605828117.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512303605828117.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","688506","BK0239","02615"],"gpt_icon":0},{"id":"1136738692","title":"百利天恒拟发行不超过100亿元债务融资工具","url":"https://stock-news.laohu8.com/highlight/detail?id=1136738692","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136738692?lang=zh_cn&edition=full","pubTime":"2025-12-28 15:50","pubTimestamp":1766908212,"startTime":"0","endTime":"0","summary":"百利天恒公告称,公司计划发行总额不超过100亿元人民币的债务融资工具。此次融资将用于优化债务结构及补充营运资金,具体发行条款将根据市场情况和公司需求确定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688506"],"gpt_icon":0},{"id":"2594221865","title":"百利天恒最新公告:拟申请注册发行不超过100亿元债务融资工具","url":"https://stock-news.laohu8.com/highlight/detail?id=2594221865","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594221865?lang=zh_cn&edition=full","pubTime":"2025-12-28 15:50","pubTimestamp":1766908207,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称,公司拟在中国银行间交易市场申请注册发行债务融资工具,发行规模不超过100亿元,品种包括中期票据、短期融资券等。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800002883.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","02615","91194","BK0239"],"gpt_icon":0},{"id":"2594077241","title":"每周股票复盘:百利天恒(688506)控股股东限售股将解禁并承诺不减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2594077241","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594077241?lang=zh_cn&edition=full","pubTime":"2025-12-28 02:17","pubTimestamp":1766859432,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘,百利天恒报收于338.55元,较上周的354.62元下跌4.53%。本周,百利天恒12月22日盘中最高价报355.48元。公司公告汇总:控股股东朱义自愿承诺限售期满后12个月内不以任何方式减持公司股份。公司公告汇总四川百利天恒药业股份有限公司首次公开发行部分限售股将于2026年1月6日上市流通,本次解除限售股份数量为298,108,880股,占公司当前总股本的72.2034%,限售期为36个月。保荐人中信证券对本次限售股上市流通事项无异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000411.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","688506","BK0239","02615"],"gpt_icon":0},{"id":"2594378092","title":"百利天恒(688506)披露首次公开发行部分限售股上市流通暨控股股东、实际控制人自愿承诺不减持的公告,12月25日股价下跌3.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594378092","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594378092?lang=zh_cn&edition=full","pubTime":"2025-12-25 22:07","pubTimestamp":1766671628,"startTime":"0","endTime":"0","summary":"截至2025年12月25日收盘,百利天恒报收于331.0元,较前一交易日下跌3.22%,最新总市值为1366.61亿元。近日,四川百利天恒药业股份有限公司发布关于首次公开发行部分限售股上市流通暨控股股东、实际控制人自愿承诺不减持的公告。公告显示,公司首次公开发行部分限售股将于2026年1月6日上市流通,本次解除限售股份数量为298,108,880股,占公司当前总股本的72.2034%,限售期为36个月。本次解除限售股东为公司控股股东、实际控制人朱义先生。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500035809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","02615","BK0239","688506"],"gpt_icon":0},{"id":"1177744413","title":"百利天恒宣布2.981亿股限售股即将解禁,1月6日起上市流通","url":"https://stock-news.laohu8.com/highlight/detail?id=1177744413","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177744413?lang=zh_cn&edition=full","pubTime":"2025-12-25 17:44","pubTimestamp":1766655876,"startTime":"0","endTime":"0","summary":"百利天恒公告称,公司约2.981亿股限售股份的锁定期即将届满,这部分股份将于1月6日起正式上市流通交易。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688506"],"gpt_icon":0},{"id":"2592974802","title":"12月18日百利天恒现292.42万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2592974802","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592974802?lang=zh_cn&edition=full","pubTime":"2025-12-18 17:51","pubTimestamp":1766051502,"startTime":"0","endTime":"0","summary":"证券之星消息,12月18日百利天恒发生大宗交易,交易数据如下:大宗交易成交价格348.12元,成交0.84万股,成交金额292.42万元,买方营业部为华泰证券股份有限公司马鞍山湖东中路证券营业部,卖方营业部为中国国际金融股份有限公司北京建国门外大街证券营业部。近三个月该股共发生3笔大宗交易,合计成交1037.0手。截至2025年12月18日收盘,百利天恒报收于348.12元,下跌0.98%,换手率0.56%,成交量5768.0手,成交额2.03亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800027318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688506","02615","91194"],"gpt_icon":0},{"id":"2590448581","title":"四川新首富豪赌创新药:叫停港股IPO,百利天恒的“输血”与“造血”困局","url":"https://stock-news.laohu8.com/highlight/detail?id=2590448581","media":"华夏时报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590448581?lang=zh_cn&edition=full","pubTime":"2025-12-10 19:50","pubTimestamp":1765367400,"startTime":"0","endTime":"0","summary":"华夏时报记者 王瑜 于娜 北京报道随着百利天恒(688506.SH)市值从百亿元跃升为千亿元,公司创始人、董事长朱义一举问鼎四川首富。这位自称“打麻将都要All in”的狠人,在创新药赛道上更是 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/20251210/c673110112.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20251210/c673110112.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992","688506","BK0239"],"gpt_icon":0},{"id":"2588371664","title":"百利天恒收到里程碑付款;迈威生物披露阻塞性肺病新药临床进展|医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2588371664","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588371664?lang=zh_cn&edition=full","pubTime":"2025-12-01 07:13","pubTimestamp":1764544408,"startTime":"0","endTime":"0","summary":"|2025年12月1日星期一|NO.1百利天恒收到百时美施贵宝里程碑付款百利天恒公告,子公司SystImmune已收到由百时美施贵宝支付的2.5亿美元里程碑付款。据合作协议,公司后续还有资格获得最高可达2.5亿美元的近期或有付款,以及在达到特定的开发、注册和销售里程碑后最高可达71亿美元的额外付款。合作协议中所约定的里程碑付款需要满足一定的条件,最终里程碑付款尚存在不确定性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512013578546745.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512013578546745.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688506","159938","688062","02615","91194","BK1515","BK1574","09939","BK0239","BK1161"],"gpt_icon":0},{"id":"1197403315","title":"四川百利天恒表示仍有资格获得高达2.5亿美元的短期付款,以及在达到特定研发、监管、商业里程碑后获得高达71亿美元的额外付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1197403315","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197403315?lang=zh_cn&edition=full","pubTime":"2025-11-30 17:18","pubTimestamp":1764494292,"startTime":"0","endTime":"0","summary":"四川百利天恒表示仍有资格获得高达2.5亿美元的短期付款,以及在达到特定研发、监管、商业里程碑后获得高达71亿美元的额外付款。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","LU1571399168.USD","BK4585","LU1989771016.USD","LU0114720955.EUR","BK0239","BK4559","BMY","IE00BFTCPJ56.SGD","LU1323610961.USD","BK4007","LU0306806265.USD","LU1670711040.USD","LU0306807586.USD","LU0882574055.USD","IE00B2B36J28.USD","LU0096364046.USD","LU2125154778.USD","IE00BFXG1179.USD","LU0321505439.SGD","LU1430594728.SGD","IE00BSNM7G36.USD","LU0321505868.SGD","LU1074936037.SGD","LU1093756168.USD","BK4532","LU1261432733.SGD","LU1670710661.SGD","LU0237698245.USD","LU1868837300.USD","LU1585245621.USD","LU2242652126.USD","IE0009355771.USD","LU2125154935.USD","LU2360032135.SGD","IE00BJT1NW94.SGD","LU0225771236.USD","LU2242646821.SGD","LU0225284248.USD","IE0002141913.USD","LU0456855351.SGD","LU0868494617.USD","LU1032466523.USD","LU0267386448.USD","LU0985481810.HKD","688506","LU1868836914.USD","LU1670711123.USD","LU0061475181.USD","LU1868836591.USD","BK4588","BK4534","LU1868836757.USD","LU1718418525.SGD","BK4581","LU2133065610.SGD","LU1868837136.USD","LU1291159041.SGD","LU1670710588.SGD","LU1093756325.SGD"],"gpt_icon":0},{"id":"1112180261","title":"百利天恒宣布其子公司近期已从施贵宝获得2.5亿美元里程碑付款,涉及Iza-Bren全球战略协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1112180261","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112180261?lang=zh_cn&edition=full","pubTime":"2025-11-30 17:18","pubTimestamp":1764494292,"startTime":"0","endTime":"0","summary":"百利天恒宣布其子公司近期已从施贵宝获得2.5亿美元的里程碑付款,涉及Iza-Bren全球战略协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","LU0237698245.USD","LU1670711040.USD","LU1074936037.SGD","LU1323610961.USD","BK4585","LU1868836914.USD","LU0225771236.USD","LU0321505439.SGD","LU1093756325.SGD","688506","IE0009355771.USD","LU0985481810.HKD","IE00BSNM7G36.USD","LU2125154778.USD","BK4534","LU0267386448.USD","BK4588","BK0239","LU1093756168.USD","LU2242652126.USD","LU1868836757.USD","LU1868837136.USD","IE00BJT1NW94.SGD","BK4581","LU1585245621.USD","LU1571399168.USD","LU0061475181.USD","LU1261432733.SGD","IE00B2B36J28.USD","BK4559","BK4532","LU1868837300.USD","BK4007","LU0306806265.USD","LU0096364046.USD","IE0002141913.USD","LU1868836591.USD","LU2360032135.SGD","LU1670710588.SGD","LU1989771016.USD","LU2133065610.SGD","IE00BFTCPJ56.SGD","LU0456855351.SGD","LU1430594728.SGD","LU1670711123.USD","LU0225284248.USD","LU2125154935.USD","LU2242646821.SGD","LU1670710661.SGD","LU0882574055.USD","LU1718418525.SGD","LU0306807586.USD","BMY","LU0114720955.EUR","LU0321505868.SGD","IE00BFXG1179.USD","LU1032466523.USD","LU0868494617.USD","LU1291159041.SGD"],"gpt_icon":0},{"id":"2587799680","title":"百利天恒(688506.SH)子公司收到与百时美施贵宝就iza-bren项目里程碑付款2.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2587799680","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2587799680?lang=zh_cn&edition=full","pubTime":"2025-11-30 16:56","pubTimestamp":1764492983,"startTime":"0","endTime":"0","summary":"智通财经APP讯,百利天恒(688506.SH)发布公告,公司全资子公司SystImmune近期收到由BMS支付的2.5亿美元里程碑付款。根据合作协议,公司后续还有资格获得最高可达2.5亿美元的近期或有付款,以及在达到特定的开发、注册和销售里程碑后最高可达71亿美元的额外付款。合作协议中所约定的里程碑付款需要满足一定的条件,最终里程碑付款尚存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1670711123.USD","LU0868494617.USD","LU1074936037.SGD","LU0096364046.USD","LU2133065610.SGD","LU1868836757.USD","IE0002141913.USD","LU2360032135.SGD","IE00BSNM7G36.USD","LU1261432733.SGD","LU1093756325.SGD","LU1670710661.SGD","LU2242652126.USD","LU1670710588.SGD","LU1868836914.USD","BK4588","LU1868836591.USD","LU1585245621.USD","LU0225771236.USD","LU0321505439.SGD","LU1718418525.SGD","IE00BFTCPJ56.SGD","BK4581","LU0114720955.EUR","LU1291159041.SGD","LU1868837136.USD","LU1430594728.SGD","IE00BJJMRZ35.SGD","LU1093756168.USD","91194","BMY","IE00BJT1NW94.SGD","IE00B2B36J28.USD","BK4559","LU2242646821.SGD","688506","LU0985481810.HKD","BK4007","LU0882574055.USD","LU2125154935.USD","BK4585","02615","LU0306807586.USD","LU0306806265.USD","LU0267386448.USD","LU1868837300.USD","BK4532","LU1032466523.USD","BK0239","LU1323610961.USD"],"gpt_icon":0},{"id":"2586722547","title":"百利天恒(688506)披露召开2025年第三季度业绩说明会公告,11月27日股价下跌0.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586722547","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586722547?lang=zh_cn&edition=full","pubTime":"2025-11-27 22:32","pubTimestamp":1764253945,"startTime":"0","endTime":"0","summary":"截至2025年11月27日收盘,百利天恒报收于384.99元,较前一交易日下跌0.85%,最新总市值为1589.52亿元。公司近日发布公告称,四川百利天恒药业股份有限公司将于2025年12月4日15:00-16:00通过上证路演中心以网络文字互动方式召开2025年第三季度业绩说明会,介绍公司经营成果、财务状况及发展战略。投资者可于2025年11月28日至12月3日16:00前通过上证路演中心预提问栏目或公司邮箱ir@baili-pharm.com提交问题。说明会结束后可通过上证路演中心查看会议内容。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700038707.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","91194","02615","BK0239"],"gpt_icon":1},{"id":"2586475897","title":"百利天恒:截至2025年9月30日,股东户数为5979户","url":"https://stock-news.laohu8.com/highlight/detail?id=2586475897","media":"证券日报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586475897?lang=zh_cn&edition=full","pubTime":"2025-11-25 21:07","pubTimestamp":1764076026,"startTime":"0","endTime":"0","summary":"证券日报网讯百利天恒11月25日在互动平台回答投资者提问时表示,截至2025年9月30日,股东户数为5,979户。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511253574450719.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","02615","688506","BK0239"],"gpt_icon":0},{"id":"1122300755","title":"四川百利天恒与中国银行四川省分行签署不少于80亿元的信贷协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1122300755","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122300755?lang=zh_cn&edition=full","pubTime":"2025-11-19 19:02","pubTimestamp":1763550123,"startTime":"0","endTime":"0","summary":"四川百利天恒表示,与中国银行四川省分行签署了不少于80亿元的信贷协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688506"],"gpt_icon":0},{"id":"2584605809","title":"百利天恒(688506.SH):iza-bren用于复发性或转移性食管鳞癌的III期临床试验的期中分析达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2584605809","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584605809?lang=zh_cn&edition=full","pubTime":"2025-11-18 08:23","pubTimestamp":1763425416,"startTime":"0","endTime":"0","summary":"智通财经APP讯,百利天恒 发布公告,公司自主研发的全球首创、新概念且唯一进入III期临床阶段的EGFR×HER3双抗ADC在食管鳞癌的III期临床试验中,经独立数据监查委员会判断,在预设的期中分析中达到无进展生存期和总生存期双主要终点,适应症为:既往经PD-1/PD-L1单抗联合含铂化疗治疗失败的复发性或转移性食管鳞癌。这是全球首个ADC药物在食管癌治疗中取得PFS/OS双阳性结果的III期临床研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370306.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK4134","III","91194","688506","02615"],"gpt_icon":0},{"id":"2583654377","title":"每周股票复盘:百利天恒(688506)H股上市延迟","url":"https://stock-news.laohu8.com/highlight/detail?id=2583654377","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583654377?lang=zh_cn&edition=full","pubTime":"2025-11-16 04:30","pubTimestamp":1763238628,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘,百利天恒报收于371.62元,较上周的349.93元上涨6.2%。本周,百利天恒11月14日盘中最高价报378.0元。本周关注点公司公告汇总:百利天恒因市场情况延迟H股全球发售及上市。公司公告汇总四川百利天恒药业股份有限公司正在推进发行H股并在香港联合交易所主板上市的工作。2025年11月7日,公司已在香港联交所网站刊登H股招股说明书及相关发售安排。公告不构成对任何个人或实体认购H股的要约或要约邀请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","688506","BK0239","91194"],"gpt_icon":0},{"id":"2583522901","title":"百利天恒IPO延迟!“A+H”还要等多久?","url":"https://stock-news.laohu8.com/highlight/detail?id=2583522901","media":"投资时报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583522901?lang=zh_cn&edition=full","pubTime":"2025-11-14 14:54","pubTimestamp":1763103240,"startTime":"0","endTime":"0","summary":"编者按:拆解企业招股、估值、上市表现,以专业视角记录资本脉动。投资时间网携手标点财经联袂锻造“解码港股IPO”特别策划,深度探寻每一次资本浪潮背后的机遇与逻辑,敬请关注。投资时间 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20251114/c672484389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0239","688506"],"gpt_icon":0},{"id":"2583028534","title":"688506,港股IPO延迟!","url":"https://stock-news.laohu8.com/highlight/detail?id=2583028534","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583028534?lang=zh_cn&edition=full","pubTime":"2025-11-13 12:39","pubTimestamp":1763008740,"startTime":"0","endTime":"0","summary":"【导读】百利天恒港股IPO再遇波折,决定延迟H股全球发售及上市11月12日晚间,百利天恒发布公告称,鉴于目前市场情况,公司决定延迟H股全球发售及上市。百利天恒2024年6月21日官宣拟在港股上 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/20251113/c672453895.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20251113/c672453895.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0239","688506"],"gpt_icon":0},{"id":"2582667377","title":"百利天恒(688506)披露关于发行H股并上市的进展公告,11月12日股价上涨2.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582667377","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582667377?lang=zh_cn&edition=full","pubTime":"2025-11-12 22:21","pubTimestamp":1762957282,"startTime":"0","endTime":"0","summary":"截至2025年11月12日收盘,百利天恒报收于360.85元,较前一交易日上涨2.49%,最新总市值为1489.86亿元。该股当日开盘348.0元,最高369.86元,最低348.0元,成交额达4.38亿元,换手率为1.18%。公司近日发布公告称,四川百利天恒药业股份有限公司正在推进发行H股并在香港联合交易所主板上市的工作。鉴于当前市场情况,公司决定延迟本次H股的全球发售及上市,并于2025年11月12日在香港联交所网站发布相关公告。公告不构成对任何个人或实体认购H股的要约或要约邀请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200041338.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","688506","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767173390188,"stockEarnings":[{"period":"1week","weight":-0.0765},{"period":"1month","weight":-0.1498},{"period":"3month","weight":-0.1403},{"period":"6month","weight":0.0828},{"period":"1year","weight":0.6743},{"period":"ytd","weight":0.6829}],"compareEarnings":[{"period":"1week","weight":0.0115},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0212},{"period":"6month","weight":0.1456},{"period":"1year","weight":0.1637},{"period":"ytd","weight":0.183}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川百利天恒药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"5979人(较上一季度增加25.08%)","perCapita":"67068股","listingDate":"2023-01-06","address":"四川省成都市温江区成都海峡两岸科技产业园百利路161号一幢一号","registeredCapital":"41287万元","survey":" 四川百利天恒药业股份有限公司的主营业务是创新生物药业务板块和化药制剂、中成药制剂业务板块。公司的主要产品是丙泊酚乳状注射液、丙泊酚中/长链脂肪乳注射液、吸入用七氟烷、结构脂肪乳注射液、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。","listedPrice":24.7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百利天恒,688506,百利天恒股票,百利天恒股票老虎,百利天恒股票老虎国际,百利天恒行情,百利天恒股票行情,百利天恒股价,百利天恒股市,百利天恒股票价格,百利天恒股票交易,百利天恒股票购买,百利天恒股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}